EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine

Andreas Karwautz iD, Michael Zeiler iD, Julia Schwarzenberg, Dunja Mairhofer, Michaela Mitterer, Stefanie Truttmann, Julia Philipp, Doris Koubek, Maria Glüder, Gudrun Wagner, Anouk Malcher, Gabriele Schöfbeck and 14 more

European Eating Disorders Review · 2024

DOI: 10.1002/erv.3022 ↗

At a glance

Journal article in European Eating Disorders Review, 2024. Written by Andreas Karwautz and 25 co-authors. Institution: Eating Disorders Care and Research Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Wien, Austria. Major MEDLINE topics: Anorexia Nervosa, Olanzapine, Drug Monitoring, Antipsychotic Agents. Cited 12 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Bundesinstitut für Arzneimittel und Medizinprodukte, German Federal Ministry of Education and Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Medication is commonly used in anorexia nervosa (AN) despite largely missing high grade evidence. Olanzapine (OLZ) is the best‐evidenced substance used off‐label in this group, with conflicting outcome regarding BMI, clinical and safety parameters. Therefore, it is important to strictly assure quality of treatment with OLZ in AN by using ‘Therapeutic Drug Monitoring’ according to AGNP‐guidelines, including serum levels and adverse drug reactions (ADRs) to support safety for adolescents with AN and attempt to generate an initial age‐ and disorder‐specific therapeutic reference range.

Method

Sixty‐five adolescents with AN (aged 10–18) treated with OLZ (98% female; 97.5% AN‐restricting‐type) were prospectively observed, ADRs reported, and correlations between dosage and serum levels measured at trough level were calculated, a preliminary therapeutic range defined.

Results

Mean dosage of OLZ was 8.15 (SD: 2.91) mg and 0.19 (SD: 0.07) mg/kg respectively, average concentration was 26.57 (SD: 13.46) ng/mL. Correlation between daily dosage/dosage per kg and serum level was 0.72 (** p < 0.001)/0.65 (** p < 0.001), respectively. ADRs with impairment were rare (6.3%). 75% improved clinically (CGI). BMI increased significantly by 1.5 kg/m 2 ( t = 10.6, p < 0.001). A preliminary therapeutic reference range is 11.9 and 39.9 ng/mL.

Conclusions

OLZ in the hands of specialists is a well‐tolerated and safe treatment adjunct for adolescents with AN.

Subjects

MeSH terms (MEDLINE)

Anorexia NervosaOlanzapineDrug MonitoringAntipsychotic AgentsHumansAdolescentFemaleMaleChildBenzodiazepinesProspective Studies

Author keywords

TDMadolescentsadverse drug reactionsanorexia nervosaolanzapine

Substances

OlanzapineAntipsychotic AgentsBenzodiazepines

Authors and institutions

  • Eating Disorders Care and Research Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Wien, Austria.
  • CIO Marburg GmbH, Fronhausen, Germany.
  • Parklandklinik, Bad Wildungen, Germany.
  • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany.
  • Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany.
  • Berlin Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité University Medical Center, Berlin, Germany.

ORCID profiles: Andreas Karwautz, Michael Zeiler, Clarissa Laczkovics, Karin Egberts

Funding

  • Bundesinstitut für Arzneimittel und Medizinprodukte
  • German Federal Ministry of Education and Research

Cite

APA

Karwautz, A., Zeiler, M., Schwarzenberg, J., Mairhofer, D., Mitterer, M., Truttmann, S., Philipp, J., Koubek, D., Glüder, M., Wagner, G., Malcher, A., Schöfbeck, G., Laczkovics, C., Rock, H. W., Zanko, A., Imgart, H., Banaschewski, T., Fleischhaker, C., Correll, C. U., …, & Gerlach, M. (2024). Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. European Eating Disorders Review. https://doi.org/10.1002/erv.3022

Vancouver

Karwautz A, Zeiler M, Schwarzenberg J, Mairhofer D, Mitterer M, Truttmann S, et al. Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. European Eating Disorders Review. 2024. doi:10.1002/erv.3022

BibTeX
@article{Karwautz2024,
  author = {Karwautz, Andreas and Zeiler, Michael and Schwarzenberg, Julia and Mairhofer, Dunja and Mitterer, Michaela and Truttmann, Stefanie and Philipp, Julia and Koubek, Doris and Glüder, Maria and Wagner, Gudrun and Malcher, Anouk and Schöfbeck, Gabriele and Laczkovics, Clarissa and Rock, Hans W and Zanko, Annika and Imgart, Hartmut and Banaschewski, Tobias and Fleischhaker, Christian and Correll, Christoph U and Wewetzer, Christoph and Walitza, Susanne and Taurines, Regina and Fekete, Stefanie and Romanos, Marcel and Egberts, Karin and Gerlach, Manfred},
  title = {Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine},
  journal = {European Eating Disorders Review},
  year = {2024},
  doi = {10.1002/erv.3022}
}
Start for free →